الأربعاء 13 ربيع الأول 1448هـ
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
تحقق من أن الموقع يستخدم بروتوكول HTTPS
مسجل لدى هيئة الحكومة الرقمية برقم :
| عنوان الدراسة | داعم الدراسة | حالة الدراسة | دواء الدراسة | مرحلة الدراسة | رقم بروتوكول الدراسة | موقع الدراسة |
|---|---|---|---|---|---|---|
| "(LUMINOUS)Study to observe the effectiveness andsafety of ranibizumab through individualized patienttreatment and associated " | Novartis | Completed | Ranibizumab 10mg/ml (Lucentis) | 4 | RFB002A2406 | King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah), Prince Sultan Military Medical City (Riyadh) |
| An observational study to evaluate the effectiveness, safty and effect on health-related quality of life of treatment in routine practice (PERFORMS) | Novartis | Completed | Fingolimod | 4 | CFTY720D-MAX-TH-01 | King Fahad Medical City (Riyadh), King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Jeddah) |
| An observational, prospective, open-label to assess effectiveness, safety and tolerability of once-yearly treatment with zoledronic acid in osteoporotic patients in a real-world setting (AZURE). | Novartis | Completed | Zoledronic acid | 4 | CZOL446H-MAX-SA-01 | King Fahad University Hospital (Al-Khobar), King Khalid University Hospital (Riyadh) |
| A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects with a Urea Cycle Disorder with Inadequate Control on Standard of Care | Kaleido Biosciences | Ongoing | KB195 | 2 | K020-218 | King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh) |
| A two part seamless, open label, multi-center study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type 1 spinal muscular atrophy. | Roche | Terminated | RO7034067 | 2 | BP39056 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS | Roche | Terminated | Ocrelizumab | 3b | MN39159 | King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh) |
| A SINGLE-ARM, MULTICENTER PHASE IIIB CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PROPHYLACTIC EMICIZUMAB IN HEMOPHILIA A PATIENTS WITH INHIBITORS | Roche | Ongoing | Emicizumab | 3 | MO39129 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| "Tranexamic acid for the treatment of gastrointestinal hemorrhage: aninternational randomized, double-blind, placebo-controlled trial" | Prince Mohammad Bin Abdulaziz Hospital | Completed | Tranexamic acid | 3 | ISRCTN11225767 | Prince Mohammad bin Abdulaziz hospital (Riyadh), King Fahad Medical City (Riyadh) |
| Randomized, two-way, two- period, single oral dose, open- label, crossover, bioequivalence study to compare Diclofenac Potassium powder for oral solution (50 mg diclofenac potassium) manufactured by Riyadh Pharma versus Catafast® powder for oral solution (50 mg diclofenac potassium) manufactured by Mipharm S.p.A., in healthy subjects under fasting condition. | Saudi Ajal | Completed | DICLOFENAC POTASSIUM | BE | 42856 | Saudi Ajal |
| A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Determine The Efficacy And Safety Of Luspatercept (Ace-536) Versus Placebo In Adults Who Require Regular Red Blood Cell Transfusions Due To Beta -Thalassemia The “BELIEVE” Trial | Celgene | Completed | Luspatercept (ACE 536) | 3 | ACE-536-B-THAL-001 | King Khalid University Hospital (Riyadh) |
تاريخ آخر تحديث: 14/09/2026 بتمام الساعة 08:25 صباحا بتوقيت المملكة العربية السعودية
لم يتم تقديم أي تقييمات لهذه الصفحة بعد.
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.